S. Merrick

Sequencing treatment for metastatic prostate cancer

S. Chowdhury, R. Kirby, S. Merrick, 2018 .

Impact of age on the toxicity of immune checkpoint inhibition

D. Josephs, G. Faust, M. van Hemelrijck, 2020, Journal for ImmunoTherapy of Cancer.

Use of diclazuril for the treatment of isosporiasis in patients with AIDS.

D. Gruen, R. Soave, S. Merrick, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers

L. Pickering, K. Edmonds, M. Nankivell, 2022, Contemporary clinical trials.

The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma

A. Sheri, S. Law, S. Merrick, 2019, Melanoma research.

Outcome and patient-reported toxicity in localised prostate cancer treated with dose-escalated hypofractionated intensity-modulated radiotherapy

R. Cowan, J. Logue, T. Elliott, 2013, Journal of Radiotherapy in Practice.

Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity

R. Cowan, J. Logue, T. Elliott, 2012, Prostate cancer.

Junior doctor dementia champions in a district general hospital (innovative practice)

A. Coates, S. Merrick, I. Wilkinson, 2016, Dementia.

PTU-006 Incidence of immune check point inhibitor induced diarrhoea/colitis- experience from a multi-centre cohort

J. Larkin, M. Gore, D. Josephs, 2018, IBD.

AN AUDIT INTO ADVANCED CARE PLANNING FOR END OF LIFE CARE PATIENTS AT KINGSTON HOSPITAL

L. Kreeger, Emily Guilhem, S. Merrick, 2014, BMJ Supportive & Palliative Care.